Chlamydia trachomatis infections cause the most common notifiable diseases in the United States, reflecting the successful adaptation of these organisms to persist in their obligate human host population. Antigenic variation of the quantitatively predominant major outer membrane protein (MOMP) is considered to play an important role in this adaptation as a means of immune evasion. The relative capacity of murine polyvalent sera produced following infection, recovery, and challenge to neutralize infectivity was highly serovar-specific and dependent upon thermolabile antigens. The structural complexity of these immunodominant antigens was mimicked by chlamydial MOMP expressed in Escherichia coli, as antibodies that neutralize infectivity by recognition of conformationdependent antigens were specifically removed from sera following absorption using MOMP expressed in E. coli.
Chlamydia trachomatis infections cause the most common notifiable diseases in the United States, reflecting the successful adaptation of these organisms to persist in their obligate human host population. Antigenic variation of the quantitatively predominant major outer membrane protein (MOMP) is considered to play an important role in this adaptation as a means of immune evasion. The relative capacity of murine polyvalent sera produced following infection, recovery, and challenge to neutralize infectivity was highly serovar-specific and dependent upon thermolabile antigens. The structural complexity of these immunodominant antigens was mimicked by chlamydial MOMP expressed in Escherichia coli, as antibodies that neutralize infectivity by recognition of conformationdependent antigens were specifically removed from sera following absorption using MOMP expressed in E. coli.
Chlamydia trachomatis is the cause of several important when this has been evaluated for trachoma [11] and for sexually transmitted infections [12] . human diseases including trachoma (the leading cause of preventable blindness), pelvic inflammatory disease, ectopic Antigenic variation of surface proteins that are the focus of pregnancy, chronic pelvic pain, epididymitis, and infant pneuantibody-mediated protection is a common theme for pathomonia [1] . C. trachomatis genital tract infections also signifigenic microorganisms [13, 14] . The combination of a wide cantly increase the risk for human immunodeficiency virus variety of MOMP-specific monoclonal antibodies with differinfection [2, 3] . Chlamydial serovariant-specific antigens may ent specificities and knowledge of the primary sequence strucbe the most effective immune-protective targets because chalture of different MOMP variants initially promised to facilitate lenge with the homologous serovar results in immune protecidentification of MOMP epitopes that would be useful for vaction, whereas challenge with heterologous serovars results in cine development. Immunization using VS1-based peptides has infection [4, 5] . Studies using Chlamydia-specific [1] monobeen shown to elicit antibody responses that can neutralize clonal antibodies have suggested that the chlamydial major infectivity in vitro [15, 16] ; however, vaccination with such outer membrane protein (MOMP) contains the serovar-defining MOMP peptides has not been successful in eliciting protective immunity in vivo. This may be because the identification of antigens and that MOMP serovar-specific antigens are the prisingle peptide epitopes and their use as immunogens have typimary targets that mediate in vitro neutralization of infectivity cally resulted in eliciting high antipeptide responses but rela- [6 -8] . The antigenic differences among chlamydial strains are tively low reactivity to native elementary bodies (EBs), the defined by variant sequence regions of MOMP, and two disconinfectious form of the organism [10, 17, 18] . Although either tinuous variant sequence regions (VS1 and VS2) have been monospecific polyvalent sera or monoclonal antibodies specific associated with serovar specificity because they bind serovarfor individual MOMP VS regions can neutralize chlamydial specific monoclonal antibodies [9, 10] . Epidemiologic data supinfectivity in vitro, there is evidence that other MOMP antigens port the view that naturally acquired immunity to C. trachomore appropriately reflect the complexity indicated by the primatis is related to serovar-specific immunity, as there is a mary sequence of MOMP and may be defined by conformachange in the distribution of MOMP allelic variants over time tional determinants [6, 19, 20] . While the use of monoclonal antibodies or synthetic peptides is ideal for some purposes, their singular specificity, even analyzed in the aggregate, has not provided a holistic understand-JID 1997;176 (September) of an inverted epifluorescence microscope and CCD camera imAssessments of neutralization following absorption of sera with aging (Photometrics, Tucson, AZ) with computer-assisted enumersynthetic peptides or native MOMP expressed in Escherichia ation (IPLab Spectrum; Signal Analytics, Vienna, VA).
coli were employed to dissect the specificity characteristics Antisera absorption. To evaluate the character of antibody of antibodies that dominate the ability of polyvalent sera to present in polyvalent sera responsible for neutralization, antisera neutralize chlamydial infectivity.
were diluted to a concentration that would yield Ç1/e (Ç63%) neutralization of infectivity and absorbed with (1) synthetic peptides corresponding to the respective serovar-specific VS1, VS2,
Materials and Methods
or VS4 antigens; (2) EBs that had been heat-treated at 4, 37, 40, Bacterial strains. C. trachomatis strains used were B/TW-5/ 50, 60, or 100ЊC; or (3) recombinant E. coli expressing the entire OT and C/TW-3/OT, which were originally obtained from C.-C.
chlamydial MOMP for serovars B or C. SPG was used for all Kuo (University of Washington, Seattle), and A/HAR-13, D/UWdilutions. The synthetic peptides used have been described [21] . 3/Cx, G/UW-57/Cx, and I/UW-12/Ur, which were provided by After absorption by addition of 100 mg/mL, antisera were tested H. D. Caldwell (Rocky Mountain Laboratories, Hamilton, MT).
by ELISA as described [21, 25] to verify that absorption had All strains were grown in L929 cells, and EB developmental forms quantitatively removed peptide-specific reactivity previously dewere purified on diatrizoate (Renografin; E. R. Squibb & Sons, scribed for these sera [21] . Princeton, NJ) gradients, aliquoted, and stored at 070ЊC. EBs were Following absorption with EBs for 30 min at 4 or 37ЊC, EBs isolated from infected host cells by sonication on ice using several were removed by centrifugation at 15,000 g for 10 min. No infec-10-s pulses from a probe sonicator (Braun-Sonic 2000; Braun tivity was detected in sera absorbed with EBs following centrifugaBiotech, Allentown, PA) to the point that little host cell debris tion. Recombinant E. coli that express chlamydial MOMP was pelleted following centrifugation at 850 g. EBs were pelleted were produced using the omp1 genes obtained from serovars B by centrifugation at 10,000 g for 20 min and suspended in 5 mL (TW-5/OT) and C (TW-3/OT) [26] as described [27] . MOMP of Hanks' balanced salt solution (HBSS). The EBs were initially expression of each recombinant was verified using serovar-specific separated from host cell material by centrifugation (18,000 rpm, and species-specific monoclonal antibodies [28] by immunofluo-SW28, 30 min) through 30% diatrizoate. The EBs were then rescence and immunoblot as described [27] . After induction of washed with HBSS and purified using discontinuous gradients MOMP expression, E. coli were washed in PBS, suspended in consisting of 30%, 40%, 45%, and 50% diatrizoate. After a wash SPG, and used unfixed for absorption of antisera. Aliquots of to remove excess diatrizoate, EBs were suspended in SPG (200 induced E. coli were evaluated concurrently by immunofluoresmM sucrose, 10 mM sodium phosphate, 5 mM L-glutamate, pH cence and by immunoblot to assess the presence of MOMP. 7.2), aliquoted, and stored frozen at 070ЊC.
Neutralization assay. The production of murine polyvalent sera was described previously [21] . Briefly, 6 groups of 30 mice Each serum pool was evaluated for its ability to neutralize Diluted sera were mixed with an equal volume of a standardized infectivity of EBs representing each of the six serovars. In inoculum (Ç3 1 10not routinely evaluated. Data for neutralization of serovar A EBs using each of the 6 sera obtained from homologous challenge are shown in figure 1. At the lowest dilution (log 4 16 Å 2), sera derived from infection with C-complex serovars A, C, and I each neutralized infectivity of serovar A EBs by ú95%, whereas sera obtained following infection with B-complex serovars (i.e., B and D) or serovar G only neutralized serovar A EBs by Ç60%. Neutralization of serovar A EBs with sera derived following infection using serovar A was substantially more effective than neutralization with sera produced using the other C-complex serovars, C and I. These data illustrate the potential for a high level of serovar specificity of neutralization. We operationally attribute neutralization as spe- serovar G sera (figure 2). The kinetics of neutralization were also similar for most serovars and homologous sera. Homologous neutralization typically began abruptly and showed a steep curve until maximal neutralization was obtained, usually within be affected by antisera potency, either quantitative or qualitative, or by differences in serovar virulence for Hak cells. Previ-2 log 4 dilutions (figure 2). At a log 4 dilution of 2, EB neutralization by homologous antisera reached at least 90%, except for ous serologic evaluation of these sera showed that they were remarkably similar in terms of antibody titers to another chlaserovars G and I, for which maximal neutralization only reached Ç65% (figure 2). Differences in neutralization could mydial protein (OMP2) and, with the exception of serovar G sera, each of the other 5 sera displayed similar reactivity to the respective homologous VS1 peptide [21] . Although serovar G sera had little reactivity to serovar G -specific VS1 peptide, it reacted strongly to circularized VS1 peptide [21] . These data suggest that differences in neutralization are probably not a function of antibody titer per se, but of qualitative differences in antibody specificity or differences in strain virulence for Hak cells. Evidence implicating increased virulence for Hak cells for serovars I and G was shown by the finding that sera elicited by serovars I and G neutralized at least one other serovar by ú90% (data not shown), suggesting these sera are quantitatively and qualitatively potent.
The sensitivity of each serovar to be neutralized by different sera can be compared by the dilution at which 50% neutralization is obtained for each pair ( figure 3) ; likewise, the ability of individual sera to neutralize different serovars can be discerned across categories in figure 3. For example, serovar A EBs were effectively neutralized by murine sera elicited following infection with serovar A EBs, although the serovar A -derived sera also effectively neutralized serovar C EBs. It is apparent from these data that neutralization using polyvalent sera is very sensitive and highly serovar-specific, even among serovars Serologic studies by Zhao et al. [21] showed that, when mice . Sera titer representing 50% neutralization of infectivity for serovar A, B, C, D, G, and I elementary bodies (EBs) using sera obtained for each of 6 serovars. 50% neutralization was determined after neutralization assays using 4-fold dilutions of sera. For each determination, SE was õ10% of total mean no. of counts. * 50% neutralization was not achieved at 1:16 dilution of sera.
cross-reacting VS1 determinants. We addressed how such sera õ10 ng/mL was sufficient to reduce anti-VS1 reactivity by 50% [21] . would perform in the context of functional neutralization. Neutralization evaluations were conducted with serovar B and D It may be concluded from these experiments that the antibody specificities present in the murine polyvalent sera to antiEBs using sera derived from priming with serovar B EBs and challenging with serovar D EBs (BD sera) or vice versa (DB gens represented by VS-region peptides, although present as determined by ELISA [21] , played little or no independent role sera). Similar to the homologous B-and D-derived sera (figure 3), each heterologous pair neutralized both serovar B and D in neutralization, even though high concentrations of monoclonal antibodies to these regions are capable of neutralization EBs and had high neutralization titers for the serovar that was used for priming (figure 4). [8, 22 ]. This appears consistent with the observations that such synthetic peptides perform poorly at eliciting neutralizing antiSera produced using heterologous pairs that were more distantly related to one another and whose EBs were neutralized body responses when used as immunogens, although they produce high anti-peptide responses [17, 18] . These results demonmutually exclusively, such as serovars C and I, were also tested. Both the CI-and IC-derived sera have been shown to recall strate that serovar-specific neutralizing antibodies were present in the convalescent sera, independent of those defined excluantibodies to the original priming serovar in addition to developing cross-reactive antibodies [21] . While serovar C EBs could sively by these VS-region synthetic peptides. Thermal lability of antigens. One of the characteristics be effectively neutralized by serovar C sera but not by serovar I sera, and serovar I EBs were only neutralized by serovar I sera of potential conformational MOMP antigens is thermal lability following mild heat treatment [6, 20] ; since antibodies (figure 3), CI sera and IC sera each could neutralize both serovars (figure 4). As with the BD and DB heterologous pairs, there was responsible for neutralization were not absorbed by VS-region synthetic peptides, the potential role of conformationa specificity preference for the original priming serovar.
Role of VS region reactivity in neutralization. Based upon dependent antibodies in neutralization was addressed by absorption of sera using heat-treated EBs. Serovar B and C the serovar specificity observed for neutralization and often similar specificity of the same sera for anti-VS1 reactivity [21] , EBs were treated at 4, 37, 40, 50, 60, and 100ЊC for 10 min and then used to absorb serovar B -and C -specific sera the serovar B -and C -derived murine sera were tested for an effect on neutralization following absorption of these sera with prior to neutralization of untreated EBs. Sera absorbed with EBs that had been heat-treated at 60 or 100ЊC retained the VS1, VS2, or VS4 synthetic peptides. Before and after absorption, the sera were tested by ELISA for seroreactivity to VSability to neutralize, whereas sera absorbed with EBs treated at 4, 37, 40, or 50ЊC had lost the ability to neutralize infectivspecific peptides, and it was confirmed that the absorption had removed all detectable antibodies specific to the respective ity ( figure 5 ). Absorption using serial dilutions of EBs pretreated at different temperatures revealed that treatment at peptides (data not shown). Following absorption with peptides (100 mg/mL), there was no change in the ability of these sera 50ЊC was intermediate in effect on the ability of EBs to absorb neutralizing antibodies ( serovar B -specific sera with E. coli expressing serovar C MOMP ( figure 7A ) and serovar C -specific sera with E. coli respectively.
These data demonstrate that B or C MOMPs expressed on the surface of E. coli absorb antibodies that recognize serovarspecific MOMP conformational determinants that on native The most straightforward interpretation of the data is that a EBs are primarily responsible for neutralization. The presence serovar-specific heat-sensitive conformational determinant(s) of heat-sensitive MOMP antigenic determinants was substantiaccounts for virtually all of the ability of the murine sera to ated by finding that E. coli that expressed MOMP and were effectively neutralize infectivity. While it is formally possible heat-treated at 100ЊC for 10 min lost the ability to absorb that a different target antigen is lost or denatured by mild neutralizing antibodies (data not shown). It can be concluded heat treatment, the observation that most of the neutralizing from these data that the conformational serovar-specific antigen specificity is serovar-specific suggests the serovariant MOMP is the prime candidate.
MOMP antigens are dominant targets of neutralization. To Table 1 . Relative effects on neutralization of infectivity by sera establish that the putative serovar-specific antigens responsible absorbed with heat-treated elementary bodies (EBs).
for neutralization are defined by MOMP, the serovar B and C MOMP genes were cloned and expressed in E. coli as described in ú98% reduction of the ability of these sera to neutralize infectivity ( figure 7) . The antigen specificity of absorption was * Log 4 dilution of EBs that absorbed 50% of ability of sera to neutralize infectivity. by the ability of a given serovar to be neutralized by sera derived from different serovars or by the ability of a given serovar-elicited serum to neutralize different serovar EBs, they show that neutralization across the B and C serogroups is definitively is MOMP and expression of the chlamydial MOMP in E. coli produces a population of MOMP that is antigenically largely ineffective, and neutralization of serovars within a seroauthentic in terms of conformation-dependent functional capabilities related to neutralization of chlamydial infectivity.
Discussion
Antigenic variation by microbial pathogens represents a fundamental virulence capability that promotes persistence by evading the host immune response. The primacy of conformational antigenic determinants that mediate chlamydial neutralization has implications for other bacterial pathogens, such as Neisseria and Borrelia species, that display antigenically variant surface proteins and have eluded understanding of structurefunction activity because of structural complexity. The immune mechanisms that define protection or resolve C. trachomatis infection in humans are not conclusively known [30] . While antibody-mediated neutralization of chlamydiae has not been directly demonstrated to be an essential mechanism for immune protection or resolution of C. trachomatis infection, four factors support the conclusion that the antibody response to the only known variant surface antigen, MOMP, is an important mediator of immunity to C. trachomatis infection: the serovar-specificity of resistance to challenge [31] , the presence of a polymorphic MOMP surface antigen [32] , the selection of MOMP allelic variants in human populations with high prevalence of chlamydial infection [11, 12] , and the demonstration that antibodies specific for serovariant-specific surface antigens can neutralize infection experimentally in vivo [6] .
Defining the immunodominant neutralizing determinants is essential to understanding immunity, whether the mechanism of neutralization in vivo is by preventing EBs from infecting host cells [33] or by the presence of surface antibody that group is preferentially serovar-specific. It appears that sera additionally demonstrated that a significant proportion of MOMP expressed in E. coli was structurally and conformationderived from serologically junior serovars, such as serovars I and G, could mediate neutralization across a broader range of ally equivalent to native MOMP antigens in EBs. We conclude from these studies using convalescent sera that serovars than senior serovars, such as serovars C and B, whose sera were highly serovar-specific for neutralization. the immunodominant and, hence, optimal targets for neutralization are represented by conformation-dependent and serovarGiven that individuals may be reinfected following resolution or treatment of previous infections, the specificity of sera specific MOMP antigens. This is a surprising conclusion with profound implications for understanding antibody-mediated to neutralize EBs was evaluated for sera derived following a primary infection with one serovar and a challenge with a immune protection and vaccine design. The data suggest that an efficacious MOMP-based chlamydial vaccine must mimic different serovar. Since challenge with serovars from different serogroups do not show serologic cross-reactivity [21] , sera conformational determinants. Monoclonal antibody studies using a variety of serovars have shown that MOMP VS1, VS2, that reflect challenge with a closely related serovar were tested. In each heterologous challenge there was an antibody recall VS4 [9, 10] , and VS3 [41] are each surface-exposed, yet antibody reactivities to individual VS peptides played a minor of the serospecificity of the priming serovar that neutralized infectivity. Neutralizing responses to the challenge serovar also role in neutralization compared with conformational antigens defined by the authentic structure of the entire protein or oligowere produced. These data suggest that boosting with closely related but distinct serovars will elicit the recall of antibodies mers of protein. This suggests that each VS region structurally participates in delimiting the penultimate conformation-depenthat are capable of neutralizing both the priming serovar and the challenge serovar not previously encountered. The preferdent neutralizing determinants. Presumably the VS2 region, having twice the sequence variation of the other VS regions, ence for higher neutralization titers for the priming serovar likely reflects the higher affinity of antibodies to the priming plays a defining role in conformation dependence. These findings may also be pertinent to the immunology of C. pneumoserovar for these sera [21] .
The neutralization data obtained following absorption of anniae, in which antisera elicited by EBs neutralize infectivity but antisera elicited by MOMP peptides could not neutralize tisera strongly support a dominant role for antibodies that recognize conformational MOMP antigens in sera derived follow- [42] . Given the findings of differences in relative efficacy of neutralization for MOMP-specific monoclonal antibodies that ing infection. Absorbed sera were tested using dilutions above maximal neutralization to design the most sensitive measure of bind different VS-region peptides and their ability to compete for binding to EBs, Brunham and Peeling [8, 30] proposed immunodominant antibodies that mediate neutralization [38] . Although monospecific [16] and monoclonal antibodies [6, 7, that eliciting antibody responses to more conserved antigenic regions, such as VS4, actually inhibit neutralization by more 39, 40] specific for single VS peptides are capable of mediating in vitro neutralization of chlamydiae and the murine polyvalent effective serovar-specific neutralizing antibodies. This rationale may be expanded to consider that using single VS regions for sera contained antibodies to VS-region peptides, absorption of the murine antisera with VS-region peptides had no effect in vaccination, such as VS1 [15] , would also be competitive and thus counter-productive for highly protective anti-MOMP antidiminishing the ability of these sera to neutralize infectivity. Absorption of sera with native EBs readily removed all ability body responses defined by conformation-dependent MOMP antigens. of sera to neutralize infectivity; however, heating EBs for 10 min at temperatures ú50ЊC resulted in loss of their ability to
The antigen conformation dependence of chlamydial neutralization and the sequence-variant character of MOMP suggest absorb neutralizing antibodies. These data demonstrate that in vitro neutralization is mediated by serovar-specific heatthat minor changes in MOMP primary sequence, found even among strains of the same serovar designation [11] , may affect sensitive antigenic determinants that are the immunodominant targets of antibodies elicited following resolution of infection the efficacy of conformation-dependent neutralization sufficiently to initially facilitate escape from rapid neutralization. in this murine model.
Koehler et al.
[27] previously demonstrated that expression This view is supported by the observation that sera obtained from several patients could neutralize a serovar D strain genoof the entire serovar L2 MOMP gene in E. coli results in surface localization of MOMP apparently inserted into the E.
typically similar to the serovar D isolate characterized as the infecting strain, but these sera could not neutralize one or more coli outer membrane. E. coli expressing chlamydial serovar B or C MOMP specifically absorbed the antibodies that mediated of very closely related serovar D variants that differ by only one or two amino acid substitutions [43] . However, our findserovar-specific neutralization, unequivocally demonstrating that serovariant neutralization of EBs was mediated by MOMP ings, that challenge with a different but related serovar elicits the recall of neutralizing antibody responses to the primary antigens. That the ability of these sera to neutralize infectivity was dependent upon antibodies recognizing MOMP serovarserovar as well as antibodies that neutralize the related serovar, suggest that a vaccine composed of relatively few serovars, specific conformational determinants and that heat treatment of E. coli abolished the ability to absorb neutralizing antibodies especially junior serovars, may be sufficient to prime individu-
